Ekso Bionics (NASDAQ:EKSO) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSOGet Rating) from a hold rating to a buy rating in a research report sent to investors on Wednesday, Zacks.com reports. The brokerage currently has $2.50 target price on the stock.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, StockNews.com assumed coverage on Ekso Bionics in a research report on Wednesday, April 27th. They issued a sell rating on the stock.

NASDAQ EKSO opened at $2.34 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.22 and a quick ratio of 6.76. The stock’s fifty day moving average price is $2.66 and its 200 day moving average price is $2.93. Ekso Bionics has a 1 year low of $2.18 and a 1 year high of $6.13.

Ekso Bionics (NASDAQ:EKSOGet Rating) last released its earnings results on Thursday, April 28th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.05. Ekso Bionics had a negative return on equity of 33.87% and a negative net margin of 90.01%. During the same period in the prior year, the business posted ($0.34) EPS. Sell-side analysts forecast that Ekso Bionics will post -1 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in EKSO. Golden State Wealth Management LLC acquired a new stake in Ekso Bionics during the 4th quarter worth about $41,000. Virtu Financial LLC acquired a new stake in Ekso Bionics during the 4th quarter worth about $101,000. Renaissance Technologies LLC acquired a new stake in Ekso Bionics during the 4th quarter worth about $204,000. Finally, Morgan Stanley grew its position in Ekso Bionics by 35,735.0% during the 1st quarter. Morgan Stanley now owns 100,338 shares of the company’s stock worth $619,000 after purchasing an additional 100,058 shares during the period. 14.65% of the stock is currently owned by institutional investors.

Ekso Bionics Company Profile (Get Rating)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Featured Stories

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.